Moderna Inc. /zigman2/quotes/205619834/composite MRNA +20.57% said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.-based biotech said it has already delivered more than 30 million doses of the vaccine to the U.S. government. About 10.1 million doses of the vaccine have by now been administered in the U.S., the company said, citing Centers for Disease Control and Prevention data. The vaccine was granted emergency use authorization by the U.S. Food and Drug Administration on Dec. 18, shortly after a separate vaccine developed by Pfizer Inc. /zigman2/quotes/202877789/composite PFE +6.11% and its German partner BioNTech SE /zigman2/quotes/214419716/composite BNTX +14.19% won the same authorization. The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. The vaccine has also been authorized for use in Canada, Israel, the European Union, the U.K. and Switzerland. Moderna shares were down 1.2% premarket, but have gained 596% in the last 12 months, while the SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI -2.72% has gained 73% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -2.27% has gained 17%.